PharmaTimes

8/13/2026

KUP101 enters clinic for advanced solid tumours

8/13/2026

SMC acceptance offers new option for patients

8/12/2026

Delayed‑release mercaptamine approved for routine use

8/12/2026

Stablepharma’s thermostable td shot delivers strong phase 1 data

8/11/2026

Regulator backs gene therapy for PKP2-ACM

8/11/2026

Programme celebrates partnership excellence

8/10/2026

Acalabrutinib combinations approved for CLL and MCL

8/10/2026

First patient enrolled in Agni-01 expansion

8/6/2026

Postmenopausal study highlights oral anabolic potential

8/5/2026

Decision expands options for eligible patients

8/5/2026

Study evaluates tri‑specific T cell engager LBL‑051

8/5/2026

Designation supports accelerated access for investigational antibody

8/4/2026

EC expands use to protect youngest children

8/4/2026

New therapy aims to tackle antibiotic resistance

8/3/2026

Regulator backs gene therapy for PKP2-ACM

8/3/2026

Regulators assess PB016 vedolizumab biosimilar applications

8/3/2026

Researchers highlight minimally invasive monitoring potential

7/30/2026

First-in-human evaluation of infinitopes’ therapeutic platform

7/30/2026

First IBAT inhibitor for PBC cholestatic pruritus

7/29/2026

Designation supports pivotal trials for emerging candidates

7/29/2026

Phase 3 data show strong benefit for two therapies

7/28/2026

First patient enrolled in pivotal coronary study

7/28/2026

European regulators move closer to approving option for young male patients

7/27/2026

New service strengthens UK access to advanced multiomics support

7/27/2026

Where the future of workplace wellbeing takes centre stage

7/23/2026

Jideytro offers option for previously treated patients

7/23/2026

Designation supports development of novel orexin therapy

7/22/2026

First patient randomised as study advances novel pan phosphate transporter inhibitor

7/22/2026

Move sharpens Mission’s focus on CNS pipeline as renal specialist takes AKI asset forward

7/21/2026

Long‑term follow‑up reinforces momentum toward registration‑enabling trial

7/21/2026

Company to showcase INSTI-powered innovation across treatment and PrEP

7/20/2026

Ardena has appointed Ariane de Ganck as Chief Scientific Officer

7/20/2026

Combined company to advance biologics for immunologically‑driven disorders

7/16/2026

Latus Bio has appointed Bethany Mancilla as Chief Business Officer

7/16/2026

Partnership to support first‑in‑human trial of EPY201 in epilepsy

7/15/2026

B. Braun has appointed Sophie Spencer as Social Value & ESG Specialist

7/15/2026

Guidance expands treatment options for patients

7/14/2026

Breakwater data show significant survival gains over standard chemotherapy

7/14/2026

At‑home autoinjector option offers new flexibility for patients and care partners

7/13/2026

Non-hormonal option to be made available for patients unsuitable for HRT

7/13/2026

Roche therapy accepted for adults ineligible for stem cell transplant

7/9/2026

Early-stage study marks milestone for regenerative medicine

7/9/2026

New option for adults with IPF and PPF

7/8/2026

SEGRAM aims to offer an alternative to glucocorticoid‑based treatment

7/8/2026

Why the UK needs a unified strategy for chronic disease and adult vaccination

7/7/2026

Second phase 3 trial shows sustained benefit and supports forthcoming regulatory submission

7/7/2026

New phase 3 trial to assess impact on disease progression, function and quality of life

7/6/2026

Option offers once‑daily semaglutide tablets for adults living with obesity

7/6/2026

Deal brings together Novartis oncology capabilities with Myricx Bio’s next‑gen ADC platform

7/2/2026

Accelerator seeks early‑stage data‑driven health ventures for five‑month programme

7/2/2026

EC backs first gene replacement therapy for broad sma population

7/1/2026

QuantumCell gains global rights to NeuroRestore platform in deal worth over USD 2.2 billion

7/1/2026

Experts join new group as therapy moves into phase 2b

6/29/2026

IROS and partners use Emirati Genome Programme to identify high-risk individuals before symptoms appear

6/29/2026

Company secures first commercial product with data for active and chronic TED

6/26/2026

Viagra vs sildenafil: what UK patients should know

6/26/2026

Why Machinery Design Standards Are the First Line of Defense Against Batch Recalls

6/25/2026

No adverse events observed as study begins in EGFR‑mutant NSCLC

6/25/2026

First immunotherapy approved for LACC in England offers new treatment option for women

6/24/2026

Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30 June in Geneva. The company said five presentations will showcase its current and future approaches to migraine prevention, including new analyses for eptinezumab and primary phase 2b PROCEED data for the investigational treatment bocunebart. Lundbeck said the […]

6/24/2026

FDA alignment secured as company prepares to begin dosing in 2026

6/23/2026

Breakwater phase 3 data show significant gains in progression‑free survival

6/23/2026

Sanofi therapy becomes first disability‑targeting medicine for nrSPMS

6/11/2026

Final draft guidance recommends D‑VRd on the NHS in England and Wales

6/11/2026

Company begins phase 1 treatment in multi‑centre VIDAR‑1 trial

6/10/2026

Study marks major milestone for CTH120 as company advances disease‑modifying ambitions

6/10/2026

Guidance paves the way for NHS access for eligible adults in England and Wales

6/9/2026

SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments

6/9/2026

Partnership grants Lilly global rights to Alzstatin ACD680

6/8/2026

Phase 3 results highlight metabolic benefits alongside weight loss

6/8/2026

Treatment set to be used in routine multiple myeloma care

6/4/2026

Late‑breaking EULAR results highlight sustained responses through week 52

6/4/2026

Commission authorisation expands access to passive measles prophylaxis for vulnerable patients

6/3/2026

Early clinical activity supports expansion into broader IgA‑mediated conditions

6/3/2026

Adding durvalumab to chemoradiation helps people avoid having their bladder removed

6/2/2026

New collaboration aims to break barriers in brain‑targeted drug discovery

6/2/2026

Aragen scales Daretabart to commercial-ready production following rapid 9‑month tech transfer

6/1/2026

Accuracy is a vital metric when confirming a spectrophotometer’s suitability

5/26/2026

Data shows survival benefit in BRAFV600E‑mutant metastatic colorectal cancer

5/26/2026

Findings strengthen rationale for EMERALD trial of engineered macrophage therapy RTX001

5/20/2026

Phase 1 study to assess safety and early efficacy of KMA‑targeting car‑t in multiple myeloma

5/20/2026

Phase 2 bridge data show consistent outcomes in patients with impaired kidney function

5/19/2026

Trial shows first head‑to‑head superiority in joint endpoints for an approved PsA biologic

5/19/2026

Baxdrostat delivers clinically meaningful blood pressure reductions in phase 3 BaxHTN trial

5/18/2026

Parsortix platform to support minimally invasive analysis across various cancer trials

5/18/2026

Data suggests microbiome co-therapy may help overcome resistance to anti‑PD‑1 treatment

5/14/2026

Asgard has appointed Prof Dr Wolfram Brugger as CMO

5/14/2026

Building trust with patient organisations in the misinformation era

5/13/2026

Belfast base will expand regulatory support, boost innovation and deepen engagement

5/13/2026

Responders achieved weight loss and improvements in physical function

5/12/2026

Lead candidate ETD001 delivers significant lung function improvement

5/12/2026

Enfortumab vedotin and pembrolizumab recommended for NHS Scotland

5/11/2026

Second national grant strengthens company’s expanding global IP estate

5/11/2026

Early safety and efficacy signals support move into repeat‑dose phase 2a trial

5/7/2026

Partnership builds on existing collaboration and adds two new UCB‑nominated projects

5/7/2026

Nihr‑funded phase 2 study to assess progesterone delivery using Callavid device

5/6/2026

Omron has appointed Virendra Shelar as CEO of Omron Europe

5/6/2026

Making partnership working business as usual

5/5/2026

Findings support once‑daily dosing and reinforce PALI‑2108’s potential

5/5/2026

Study expands evaluation of survivin‑targeting vaccine